Docteur Olivier FAKIH

Bibliographie

• Bacterial translocation and intestinal permeability in early axial spondyloarthritis association with 5-year outcomes: insights from the DESIR cohort

  2026

  ArticleRheumatology

• When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

  2025

  ArticleRMD Open : Rheumatic & Musculoskeletal Diseases

• Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica

  2024

  ArticleJoint Bone Spine

• Manifestation cutanée suite à une arthrite réactionnelle

  2020

  ArticleRevue du Rhumatisme

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CHU JEAN MINJOZ BESANCON

  3 Boulevard FLEMING, 25030 Besançon

  ☎ 0381668166Hospitalier🏥 Centre CHU ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (2)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Un Noël en musique au CHU de Besançon - Hebdo25

  📰 Hebdo25 · 29/12/2023

  <a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE5lSlpSOFF6V3IzNjlsTW9GTVpoX0NZU29xZk1HcXlVc2F1U2ctNE1XamZmRkRzQWxiMG55UGFFcE5Wcy13Wk84Q2Y2Y3NGdm9hWVdyVDNkQzY1R0I3SzcyOVhSUXdzZ1BIWmhicDFBd2J3UzBuNEE?oc=5" target="_blank">Un Noël en musique au CHU de Besançon</a>&nbsp;&nbsp;<font color="#6

• Besançon. Un étudiant du CHU de Besançon présente son travail aux États-Unis - Hebdo25

  📰 Hebdo25 · 06/12/2022

  <a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPejFHVEQ3RVBfdmJYQTJjdnI2VlJ1c245OXV2QXJwNi1IQmtOUWRib21SQ3FfTlh3dTlXQ19aV19YT3Mta093eFMxQUktZzdVVlZrQzBTSlEtOFF6X1daQVhSTUFLVG9LNThnR2Q5NHNqMURKX0VST2pMR2prMDl2Mm5CT3dfZGM3WUx4UERpbnRUZkhyRW5rcmJwbVA?oc=5" target="_blank">Besançon. Un étu

Top publications · les plus citées

• 1

  Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study

  RMD open · 2023

  📚 23 citations🎯 RCR 3.83Top 11% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Objectives To determine the cumulative incidence and identify the factors associated with difficult-to-treat axial spondyloarthritis (D2T-axSpA) in French patients newly benefiting from the French ‘long-term illness’ (LTI) social security scheme for axial spondyloarthritis (axSpA). Methods This national cohort study was based on the French National Medico-Administrative Database, SNDS, which contains data on hospitalisation, LTI and outpatient care consumption. All French patients newly receiving LTI benefits for ankylosing spondylitis (AS) between 2010 and 2013 were included in the study. In France, LTI is required to access biological/targeted synthetic DMARDs (b/tsDMARDs). The follow-up period ended on 31 December 2018. So-called D2T-axSpA was defined as the failure of three b/tsDMARDs or of two b/tsDMARDs with different modes of action. Comorbidities and extra-musculoskeletal manifestations were identified using previously described algorithms. Characteristics were compared between patients with D2T-axSpA and patients with non-D2T-axSpA who had received at least one b/tsDMARD with bivariate and multivariate analysis using logistic regression. Incidence rates of major cardiovascular event (MACE) and death were compared using competitive risk analysis. Results 22 932 patients were included. 10 798 (47.08%) patients received at least one bDMARD. None received tsDMARD. During follow-up, 2115 patients were classified as having D2T-axSpA, representing 19.59% of patients who received at least one bDMARD. In multivariate analysis, D2T-axSpA was significantly associated with female gender, peripheral involvement, psoriasis, hypertension and depression (p&lt;0.001 for each case). There was no difference in the incidence of MACE (p=0.92) or death (p=0.87). Conclusion D2T-axSpA affects one in five patients exposed to bDMARDs in this national cohort. D2T-axSpA is more common in women and patients with peripheral involvement and/or comorbidities.

• 2

  Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study

  Rheumatology (Oxford, England) · 2023

  📚 18 citations🎯 RCR 2.78Top 18% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Objectives The objectives of this study were to describe the incidence of major adverse cardiovascular events (MACEs) in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. Methods This national cohort study was based on the French national medico-administrative database SNDS containing data on hospitalization, the LTI, and outpatient care consumption. All French patients newly receiving LTI benefits for AS from 2010 to 2013 were included. The final follow-up date was 31 December 2018. The occurrences of MACEs [stroke and myocardial infarction (MI)] and comorbidities were identified from algorithms previously described in the literature. Competitive risk analysis using propensity score and inverse weighting was performed to calculate cumulative incidence functions and to determine subhazard ratios (SHRs) for the various treatments of interest. Results Between 2010 and 2013, 22 929 patients were included [mean age 43.0 (s.d. 13.9) years, 44.9% mal]. The 8-year cumulative incidences of MACE, stroke, and MI were 1.81% (1.61–2.05), 0.97% (0.83–1.14), and 0.85% (0.71–1.04), respectively. NSAIDs [SHR: 0.39 (0.32–0.50), P &amp;lt; 0.001] and anti-TNF [SHR 0.61 (0.46–0.80), P &amp;lt; 0.001], but not anti-IL17 [2.10 (0.79–5.57)] were associated with a lower risk of MACE occurrence. Conclusion MACE incidence rates at 8 years are low in patients newly benefiting from LTI for AS. Our results support the hypothesis of a protective role of NSAIDs and anti-TNF in cardiovascular risk in these patients.

• 3

  Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica

  Joint bone spine · 2024

  📚 12 citations🎯 RCR 3.28Top 14% NIH🩺 Clinique🔓 Open Access

Publications scientifiques (31) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche